BRCA1 and ovarian carcinoma: All the four key landmark trials, including PAOLA-1, SOLO-1, VELIA, and PRIMA, demonstrated a greater PFS benefit of PARP inhibitors in newly diagnosed, ovarian cancer patients with BRCAm; SOLO-1 is the only study that included 388 patients with centrally confirmed germline BRCA1/2 mutation and 2 patients with centrally confirmed somatic BRCA1/2 mutations (Moore et al., 2018, González et al., 2019, Ray-Coquard et al., 2019, NCT03737643: Clinical trials gov).